STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report.

Linlin ZhangPing XiaoFanlu MengDiansheng Zhong

Published in: Current oncology (Toronto, Ont.) (2022)

STRN-ALK fusion is a rare ALK rearrangement identified in non-small cell lung cancer (NSCLC) patients. Here, we reported a case of lung adenocarcinomas with brain metastasis, harboring STRN-ALK fusion, responded well to ensartinib. This case report could provide more information for the therapeutic strategy selecting of NSCLC patients harboring STRN-ALK fusion.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
small cell lung cancer
ejection fraction
peritoneal dialysis
healthcare
resting state
epidermal growth factor receptor
patient reported outcomes
health information
social media
patient reported